Plain-English translation of NCT06494995 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new type of immunotherapy medication that works by helping your immune system fight cancer cells. You would receive this medication combined with low-dose radiation therapy — and depending on which treatment group you're assigned to, you may also receive a type of oral chemotherapy. The goal is to see if this combination approach is safe and effective for people whose head and neck cancer has returned or spread after their initial treatment didn't work.
After first-line treatment for advanced head and neck cancer fails, there aren't many proven options for what to do next. Recent research suggests that combining low-dose radiation with immunotherapy medications could work better together than either treatment alone, because the radiation may help reshape the tumor environment in a way that makes the immune system better able to fight cancer.
You likely qualify if…
You likely don't qualify if…
You will receive (the immunotherapy medication) on a regular schedule, combined with low-dose radiation therapy targeting your cancer. You'll be assigned to one of two groups: one receiving radiation plus a daily oral chemotherapy pill (), or another receiving radiation plus occasional higher-dose radiation to specific tumor spots. You'll have regular clinic visits for blood work, imaging scans, and physical exams to monitor how you're responding to treatment and any side effects. The trial involves about 52 patients total and is currently recruiting participants.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China